Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity

Background: The past few decades have seen the emergence both of new neuromodulation treatment protocols and novel applications of standard neuromodulation interventions in psychiatry. Yet little is known about different stakeholders' views about these interventions. Methods: We administered an...

Full description

Bibliographic Details
Main Authors: L.Y. Cabrera, E.D. Achtyes, R. Bluhm, A.M. McCright
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Comprehensive Psychiatry
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0010440X23000020
_version_ 1811161906156666880
author L.Y. Cabrera
E.D. Achtyes
R. Bluhm
A.M. McCright
author_facet L.Y. Cabrera
E.D. Achtyes
R. Bluhm
A.M. McCright
author_sort L.Y. Cabrera
collection DOAJ
description Background: The past few decades have seen the emergence both of new neuromodulation treatment protocols and novel applications of standard neuromodulation interventions in psychiatry. Yet little is known about different stakeholders' views about these interventions. Methods: We administered an online survey with an embedded video vignette experiment to four national samples: the general public (N = 1022), caregivers for people with depression (N = 1026), patients living with depression (N = 1050), and board-certified psychiatrists (N = 505). We randomly assigned subjects to one of eight conditions in our full factorial design: four neuromodulation interventions [electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, or adaptive brain implants] by two depression severity levels [moderate or severe]. In this paper we present results from ANOVA and linear regression models explaining how views about these four neuromodulation interventions—as measured in five attitudinal scales (general affect, perceived influence on self, perceived benefit, perceived risk, and perceived invasiveness)—vary by (1) intervention, (2) depression severity, and/or (3) stakeholder group. Results: Our results provide evidence that psychiatrists views differ significantly in important ways from other stakeholder groups. Type of intervention also shaped participants' attitudes, including perceptions of invasiveness, effectiveness, and safety. Conclusions: Given the differing affective valence among stakeholders and the differences found by modality and stakeholder groups across the different scales, future targeted educational initiatives could be developed to help address key misunderstandings and misinformed perceptions.
first_indexed 2024-04-10T06:21:34Z
format Article
id doaj.art-56b6649c481b4a4d8fa24209d4abe365
institution Directory Open Access Journal
issn 0010-440X
language English
last_indexed 2024-04-10T06:21:34Z
publishDate 2023-04-01
publisher Elsevier
record_format Article
series Comprehensive Psychiatry
spelling doaj.art-56b6649c481b4a4d8fa24209d4abe3652023-03-02T04:58:39ZengElsevierComprehensive Psychiatry0010-440X2023-04-01122152365Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severityL.Y. Cabrera0E.D. Achtyes1R. Bluhm2A.M. McCright3Pennsylvania State University, University Park, PA 18602, USA; Corresponding author at: Center for Neural Engineering, Department of Engineering Science and Mechanics, Research Associate, Rock Ethics Institute, Affiliate Associate Professor Huck Institutes of Life Sciences, The Pennsylvania State University, W-316 Millennium Science Complex, University Park, PA 16802, USA.Michigan State University, Grand Rapids, MI 49503, USAMichigan State University, 368 Farm Lane, East Lansing, MI 48824, USAMichigan State University, 509 East Circle Drive, Room 317, East Lansing, MI 48824, USABackground: The past few decades have seen the emergence both of new neuromodulation treatment protocols and novel applications of standard neuromodulation interventions in psychiatry. Yet little is known about different stakeholders' views about these interventions. Methods: We administered an online survey with an embedded video vignette experiment to four national samples: the general public (N = 1022), caregivers for people with depression (N = 1026), patients living with depression (N = 1050), and board-certified psychiatrists (N = 505). We randomly assigned subjects to one of eight conditions in our full factorial design: four neuromodulation interventions [electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, or adaptive brain implants] by two depression severity levels [moderate or severe]. In this paper we present results from ANOVA and linear regression models explaining how views about these four neuromodulation interventions—as measured in five attitudinal scales (general affect, perceived influence on self, perceived benefit, perceived risk, and perceived invasiveness)—vary by (1) intervention, (2) depression severity, and/or (3) stakeholder group. Results: Our results provide evidence that psychiatrists views differ significantly in important ways from other stakeholder groups. Type of intervention also shaped participants' attitudes, including perceptions of invasiveness, effectiveness, and safety. Conclusions: Given the differing affective valence among stakeholders and the differences found by modality and stakeholder groups across the different scales, future targeted educational initiatives could be developed to help address key misunderstandings and misinformed perceptions.http://www.sciencedirect.com/science/article/pii/S0010440X23000020ElectroceuticalsNeuromodulationNeurostimulationDepressionAttitudesStakeholders
spellingShingle L.Y. Cabrera
E.D. Achtyes
R. Bluhm
A.M. McCright
Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
Comprehensive Psychiatry
Electroceuticals
Neuromodulation
Neurostimulation
Depression
Attitudes
Stakeholders
title Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
title_full Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
title_fullStr Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
title_full_unstemmed Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
title_short Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity
title_sort views about neuromodulation interventions for depression by stakeholder group treatment modality and depression severity
topic Electroceuticals
Neuromodulation
Neurostimulation
Depression
Attitudes
Stakeholders
url http://www.sciencedirect.com/science/article/pii/S0010440X23000020
work_keys_str_mv AT lycabrera viewsaboutneuromodulationinterventionsfordepressionbystakeholdergrouptreatmentmodalityanddepressionseverity
AT edachtyes viewsaboutneuromodulationinterventionsfordepressionbystakeholdergrouptreatmentmodalityanddepressionseverity
AT rbluhm viewsaboutneuromodulationinterventionsfordepressionbystakeholdergrouptreatmentmodalityanddepressionseverity
AT ammccright viewsaboutneuromodulationinterventionsfordepressionbystakeholdergrouptreatmentmodalityanddepressionseverity